Label: LYSODREN- mitotane tablet

  • NDC Code(s): 0015-3080-60
  • Packager: E.R. Squibb & Sons, L.L.C.
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: New Drug Application

Drug Label Information

Updated May 23, 2017

If you are a consumer or patient please visit this version.

  • BOXED WARNING(What is this?)

    WARNING: ADRENAL CRISIS IN THE SETTING OF SHOCK OR SEVERE TRAUMA

    In patients taking LYSODREN, adrenal crisis occurs in the setting of shock or severe trauma and response to shock is impaired. Administer hydrocortisone, monitor for escalating signs of shock and discontinue LYSODREN until recovery [see Dosage and Administration (2.2) and Warnings and Precautions (5.1)].

    Close
  • HIGHLIGHTS OF PRESCRIBING INFORMATION
    These highlights do not include all the information needed to use LYSODREN safely and effectively. See full prescribing information for LYSODREN.
    LYSODREN ® (mitotane) tablets, for oral use
    Initial U.S. Approval: 1970

    WARNING: ADRENAL CRISIS IN THE SETTING OF SHOCK OR SEVERE TRAUMA

    See full prescribing information for complete boxed warning.

    In patients taking LYSODREN, adrenal crisis occurs in the setting of shock or severe trauma and response to shock is impaired. Administer hydrocortisone, monitor for escalating signs of shock and discontinue LYSODREN until recovery. (2.25.1)

    RECENT MAJOR CHANGES

    Ovarian Macrocysts in Premenopausal Women (5.5)                                    5/2017

    INDICATIONS AND USAGE

    LYSODREN is an adrenal cytotoxic agent indicated for the treatment of inoperable, functional or nonfunctional, adrenal cortical carcinoma. (1)

    DOSAGE AND ADMINISTRATION

    •Initial dose: 2 g to 6 g orally daily, in three or four divided doses. (2.1)

    •Increase dose incrementally to achieve a blood concentration of 14 to 20 mg/L, or as tolerated. (2.1)

    DOSAGE FORMS AND STRENGTHS

    Tablets: 500 mg, scored (3)

    CONTRAINDICATIONS

    None (4)

    WARNINGS AND PRECAUTIONS

    •Central Nervous System (CNS) Toxicity: Plasma concentrations exceeding 20 mcg/mL are associated with a greater incidence of toxicity. (5.2)

    •Adrenal Insufficiency: Institute steroid replacement as clinically indicated. Measure free cortisol and corticotropin (ACTH) levels to achieve optimal steroid replacement. (5.3)

    •Embryo-Fetal Toxicity: Can cause fetal harm. Advise women of reproductive potential of the potential risk to a fetus and use of effective contraception. (5.4, 8.1, 8.3)

    •Ovarian Macrocysts in Premenopausal Women: Advise women to seek medical advice if they experience gynecological symptoms such as vaginal bleeding and/or pelvic pain. (5.5)

    ADVERSE REACTIONS

    Common adverse reactions (≥15%) include: anorexia, nausea, vomiting and diarrhea; depression, dizziness or vertigo; and rash. (6)

    To report SUSPECTED ADVERSE REACTIONS, contact Bristol-Myers Squibb or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

    DRUG INTERACTIONS

    Adjust dosage of concomitant coumarin-type anticoagulants as needed. (7.2)

    USE IN SPECIFIC POPULATIONS

    Lactation: Do not breastfeed. (8.2)
    Hepatic Impairment: Administer LYSODREN with caution to patients with hepatic impairment. (8.6)

    See 17 for PATIENT COUNSELING INFORMATION.

    Revised: 5/2017

    Close
  • FULL PRESCRIBING INFORMATION: CONTENTS*
  • 1 INDICATIONS AND USAGE

    LYSODREN is indicated for the treatment of patients with inoperable, functional or nonfunctional, adrenal cortical carcinoma.

    Close
  • 2 DOSAGE AND ADMINISTRATION

    2.1 Recommended Dose

    The recommended initial dose of LYSODREN is 2 g to 6 g orally, in three or four divided doses per day. Increase doses incrementally to achieve a blood concentration of 14 to 20 mg/L, or as tolerated.

    LYSODREN is a cytotoxic drug. Follow applicable special handling and disposal procedures.

    2.2 Dose Modifications

    Adrenal Crisis in the Setting of Shock or Severe Trauma

    Discontinue LYSODREN until recovery [see Warnings and Precautions (5.1)].

    Central Nervous System (CNS) Toxicity

    Discontinue LYSODREN until symptoms resolve. Seven to 10 days after symptoms resolve, restart at a lower dose (for example, decrease by 500-1000 mg) [see Warnings and Precautions (5.2)].

    Close
  • 3 DOSAGE FORMS AND STRENGTHS

    500 mg white, round, biconvex, scored tablets, bisected on one side and impressed with “BL” over “L1” on the other side.

    Close
  • 4 CONTRAINDICATIONS

    None.

    Close
  • 5 WARNINGS AND PRECAUTIONS

    5.1 Adrenal Crisis in the Setting of Shock or Severe Trauma

    In patients taking LYSODREN, adrenal crisis occurs in the setting of shock or severe trauma and response to shock is impaired. Administer hydrocortisone, monitor for escalating signs of shock, and discontinue LYSODREN until recovery [see Dosage and Administration (2.2)].

    5.2 CNS Toxicity

    CNS toxicity, including sedation, lethargy, and vertigo, occurs with LYSODREN treatment. Mitotane plasma concentrations exceeding 20 mcg/mL are associated with a greater incidence of toxicity.

    5.3 Adrenal Insufficiency

    Treatment with LYSODREN can cause adrenal insufficiency. Institute steroid replacement as clinically indicated. Measure free cortisol and corticotropin (ACTH) levels to achieve optimal steroid replacement.

    5.4 Embryo-Fetal Toxicity

    LYSODREN can cause fetal harm when administered to a pregnant woman. Abnormal pregnancy outcomes, such as preterm births and early pregnancy loss, can occur in patients exposed to mitotane during pregnancy. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with LYSODREN and after discontinuation of treatment for as long as mitotane plasma levels are detectable [see Use in Specific Populations (8.18.3)].

    5.5 Ovarian Macrocysts in Premenopausal Women

    Ovarian macrocysts, often bilateral and multiple, have been reported in premenopausal patients receiving LYSODREN. Complications from these cysts, including adnexal torsion and hemorrhagic cyst rupture, have been reported. In some cases, improvement after mitotane discontinuation has been described. Advise female patients to seek medical care if they experience gynecological symptoms such as vaginal bleeding and/or pelvic pain [seeAdverse Reactions (6)].

    Close
  • 6 ADVERSE REACTIONS

    The following adverse reactions are discussed in greater detail in other sections of the label:

    •  Adrenal Crisis in the Setting of Shock or Severe Trauma [see Warnings and Precautions (5.1)]

    •   CNS Toxicity [seeWarnings and Precautions (5.2)]

    •   Adrenal Insufficiency [seeWarnings and Precautions (5.3)]
    •   Ovarian macrocysts [seeWarnings and Precautions (5.5)]

    The following adverse reactions associated with the use of LYSODREN were identified in clinical trials or postmarketing reports. Because these reactions were reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure.

    Common adverse reactions occurring with LYSODREN treatment include:

    •Anorexia, nausea, vomiting, and diarrhea (80%)

    •Depression, dizziness, or vertigo (15%-40%)

    •Rash (15%)•Neutropenia•Growth retardation, hypothyroidism

    •Confusion, headache, ataxia, mental impairment, weakness, dysarthria

    •Maculopathy•Hepatitis, elevation of liver enzymes•Gynecomastia

    •   Hypercholesterolemia, hypertriglyceridemia

    • Decreased blood androstenedione and decreased blood testosterone in females, increased sex hormone binding globulin in females      and males, decreased blood free testosterone in males.

    Less common adverse reactions include: visual blurring, diplopia, lens opacity, retinopathy, prolonged bleeding time, hematuria, hemorrhagic cystitis, albuminuria, hypertension, orthostatic hypotension, flushing, generalized aching, and fever.

    Close
  • 7 DRUG INTERACTIONS

    7.1 CYP3A4 Substrates

    Mitotane is a strong inducer of cytochrome P450 3A4 (CYP3A4). Monitor patients for a change in dosage requirements for the concomitant drug when administering LYSODREN to patients receiving drugs that are substrates of CYP3A4.

    7.2 Warfarin

    When administering coumarin-type anticoagulants to patients receiving LYSODREN, monitor coagulation tests and adjust the anticoagulant dose as needed.

    Close
  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary

    LYSODREN can cause fetal harm. Limited postmarketing cases report preterm births and early pregnancy loss in women treated with LYSODREN during pregnancy. Animal reproduction studies have not been conducted with mitotane. Advise pregnant women of the potential risk to a fetus. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

    8.2 Lactation

    Risk Summary

    Mitotane is excreted in human milk; however, the effect of LYSODREN on the breastfed infant, or effect on milk production is unknown. Because of the potential for serious adverse reactions in the breastfed infant, advise nursing women that breastfeeding is not recommended during treatment with LYSODREN and after discontinuation of treatment for as long as mitotane plasma levels are detectable.

    8.3 Females and Males of Reproductive Potential

    Contraception

    Females

    LYSODREN can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)]Advise female patients of reproductive potential to use effective contraception during treatment with LYSODREN and after discontinuation of therapy for as long as mitotane plasma levels are detectable [see Clinical Pharmacology (12.3)].

    8.4 Pediatric Use

    Safety and effectiveness in pediatric patients have not been established.

    8.5 Geriatric Use

    Clinical studies of LYSODREN did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently than younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

    8.6 Hepatic Impairment

    Hepatic impairment may interfere with the metabolism of mitotane and the drug may accumulate. Administer LYSODREN with caution to patients with hepatic impairment.

    Close
  • 11 DESCRIPTION

    LYSODREN (mitotane) is an oral adrenal cytotoxic agent. The chemical name is (±)-1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl) ethane (also known as o,p′-DDD). The chemical structure is:

    Image Mitotane Chemical Structure

    Mitotane is a white granular solid composed of clear colorless crystals. It is tasteless and has a slight pleasant aromatic odor. It is soluble in ethanol and has a molecular weight of 320.05.

    Inactive ingredients in LYSODREN are: microcrystalline cellulose, polyethylene glycol 3350, silicon dioxide, and starch.

    Close
  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Mitotane is an adrenal cytotoxic agent with an unknown mechanism of action. Mitotane modifies the peripheral metabolism of steroids and directly suppresses the adrenal cortex. A reduction in 17-hydroxycorticosteroids in the absence of decreased corticosteroid concentrations and increased formation of 6-β-hydroxycortisol have been reported.

    12.2 Pharmacodynamics

    The pharmacodynamics of mitotane are unknown.

    12.3 Pharmacokinetics

    Absorption

    Following oral administration of LYSODREN, 40% of the dose is absorbed.

    Distribution

    Mitotane is found in most tissues of the body; however, fat is the primary site of distribution.

    Elimination

    Following discontinuation of mitotane, the plasma terminal half-life ranges from 18 to 159 days (median 53 days).

    Metabolism

    Mitotane is converted to a water-soluble metabolite.

    Excretion

    No unchanged mitotane is found in urine or bile. Approximately 10% of the administered dose is recovered in the urine as a water-soluble metabolite. A variable amount of metabolite (1%-17%) is excreted in the bile.

    Close
  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    The carcinogenicity and mutagenicity of mitotane are unknown.

    Close
  • REFERENCES
  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    LYSODREN tablets are supplied as 500 mg white, round, biconvex, scored tablets, bisected on one side and impressed with “BL” over “L1” on the other side.

    100 tablets per bottle: NDC 0015-3080-60

    Store bottles at 25°C (77°F); excursions permitted between 15°C and 30°C (59°F-86°F).

    Mitotane is a cytotoxic drug. Follow applicable special handling and disposal procedures [see References (15)].

    Close
  • 17 PATIENT COUNSELING INFORMATION

    Adrenal Crisis

    Advise patients to discontinue LYSODREN in the case of shock or severe trauma and contact their healthcare provider immediately.
    Advise patients to tell their healthcare provider of any planned surgeries.

    Ovarian Macrocysts

    • Advise premenopausal women to seek medical care if they experience gynecological symptoms such as vaginal bleeding and/or pelvic pain [see Warnings and Precautions(5.5)].

    Embryo-Fetal Toxicity

    Advise females of reproductive potential of the potential risk to a fetus and to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions (5.4) and Use in Specific Populations (8.1)].
    Advise females of reproductive potential to use effective contraception during treatment and after discontinuation of treatment for as long as instructed by their healthcare provider [see Use in Specific Populations (8.3)].

    Lactation

    Advise females who are nursing not to breastfeed during treatment with LYSODREN [see Use in Specific Populations (8.2)].
    Close
  • SPL UNCLASSIFIED SECTION

    Manufactured for:
    Bristol-Myers Squibb Company
    Princeton, New Jersey 08543 USA


    TBD

    Close
  • LYSODREN 500 mg Tablets Representative Packaging

    See How Supplied section for a complete list of available packages of LYSODREN.

    NDC 0015-3080-60
    100 TABLETS
    LYSODREN® (mitotane tablets, USP)
    EACH TABLET CONTAINS 500 mg
    Rx only
    Bristol-Myers Squibb

    Image Lysodren 500 mg Tablets Label
    Close
  • INGREDIENTS AND APPEARANCE
    LYSODREN 
    mitotane tablet
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0015-3080
    Route of Administration ORAL
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    mitotane (UNII: 78E4J5IB5J) (mitotane - UNII:78E4J5IB5J) mitotane 500 mg
    Inactive Ingredients
    Ingredient Name Strength
    cellulose, microcrystalline (UNII: OP1R32D61U)  
    polyethylene glycol 3350 (UNII: G2M7P15E5P)  
    silicon dioxide (UNII: ETJ7Z6XBU4)  
    Product Characteristics
    Color white Score 2 pieces
    Shape ROUND Size 13mm
    Flavor Imprint Code BL;L1
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0015-3080-60 100 in 1 BOTTLE; Type 0: Not a Combination Product 06/01/2009
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA NDA016885 06/01/2009
    Labeler - E.R. Squibb & Sons, L.L.C. (968242821)
    Close